A patient is diagnosed with invasive mucormycosis following COVID-19 infection. Which of the following antifungal agents has NO activity against Mucor species and should be avoided?

1. A

   A. Voriconazole

2. B

   B. Isavuconazole

3. C

   C. Posaconazole

4. D

   D. Liposomal Amphotericin B

Appeared in: INI-CET EXAM -2026

Explanation

• Voriconazole has no clinically significant activity against the fungi that cause mucormycosis (order Mucorales).
• The fungi are intrinsically resistant to voriconazole, making it an ineffective treatment.
• Administering voriconazole for a suspected but unconfirmed mold infection can delay appropriate therapy and may select for resistant Mucorales, potentially worsening the patient's outcome.
• Guidelines for treating mucormycosis explicitly exclude voriconazole and recommend other agents.

Why Other Options Were Wrong

• Option B: Isavuconazole is incorrect because it is a broad-spectrum triazole antifungal that is approved by regulatory bodies like the FDA for the first-line treatment of invasive mucormycosis.
• Option C: Posaconazole is incorrect because it is another broad-spectrum triazole with proven activity against Mucorales. It is recommended for step-down or salvage therapy in mucormycosis.
• Option D: Liposomal Amphotericin B is incorrect because it is the gold standard and recommended first-line therapy for nearly all forms of invasive mucormycosis due to its potent fungicidal activity.

Related Visual

Clinical Relevance

• Nursing practice connection: Use the key finding related to Pharmacology of antifungal agents and their spectrum of activity, specifically in the context of invasive mucormycosis to guide bedside assessment, documentation, and the next nursing action.
• Accurate and rapid diagnosis of the causative fungal pathogen is critical. Mistaking mucormycosis for aspergillosis (for which voriconazole is a first-line treatment) and starting the wrong antifungal can be a fatal error.
• The recent surge in post-COVID-19 mucormycosis cases, particularly associated with uncontrolled diabetes and corticosteroid use, has made it imperative for nurses and clinicians to be aware of the correct treatment protocols.
• Nurses administering antifungal agents must be aware of their specific indications and potential for adverse effects, such as the nephrotoxicity of Amphotericin B, which may necessitate a switch to an azole like Isavuconazole or Posaconazole.

How to Approach the Question

• Identify the key elements of the question: the diagnosis is invasive mucormycosis, and you need to find the drug that should be AVOIDED.
• This is a 'negative' question. Your goal is to eliminate the drugs that ARE effective for mucormycosis.
• Recall the first-line treatment for mucormycosis. This is Liposomal Amphotericin B. Eliminate this option.
• Consider the azole antifungals. Recall that mucormycosis is a notoriously difficult-to-treat infection that requires specific, broad-spectrum azoles. Posaconazole and Isavuconazole are the two key azoles with activity against Mucorales. Eliminate these options.
• The remaining option is Voriconazole. Recall that while it is a powerful antifungal, its primary use is for aspergillosis, and it has a well-known, critical gap in its spectrum of activity against Mucorales.
• Therefore, Voriconazole is the drug that has no activity and must be avoided.

Concept Tested & Keywords

• Concept Tested: Pharmacology of antifungal agents and their spectrum of activity, specifically in the context of invasive mucormycosis.
• Stem keywords: invasive mucormycosis, COVID-19, antifungal agents, Mucor species
• Lead-in keywords: NO activity, should be avoided
• Clinical cues: Patient diagnosed with invasive mucormycosis, a specific and severe fungal infection.
• Clinical cues: The question asks for a drug to AVOID, implying a lack of efficacy or potential for harm.

Question ID

QuUaKzt8szIHraYEPrF52k

Copy ID

Reference Book

E6 Pharmacology Katzung 16e p. 1334-1336

E6 Nelson Textbook of Pediatrics(2024) — Volume 1 p. 1949-1951